Studies have continued to provide evidence that estrogen receptors (ERs), mainly subtype ERβ, are consistently expressed in lung cancer tissues and adenocarcinoma cell lines [7–9] and that high expression of ERβ predicts a very poor prognosis in lung cancer patients [7, 10–12]. This evidence concerns the gene ESR2 and lung carcinoma.